【摘要】 目的:探讨雷公藤多苷联合咪唑斯汀对皮炎湿疹患者炎症因子水平的影响。方法:选择2018年4月—2019年1月我院收治的92例皮炎湿疹患者作为研究对象,按随机数字表法分为对照组和观察组,各46例。对照组给予咪唑斯汀(10 mg,qd)治疗,观察组在此基础上联合给予雷公藤多苷[1～1.5 mg/(kg·d)]治疗,比较两组疗效、症状积分、炎症因子及不良反应。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P <0.05);治疗1、2、3周后,两组症状积分均低于治疗前,且观察组低于对照组,差异有统计学意义(P <0.05);治疗后,两组白细胞介素(IL)-2、IL-6及C反应蛋白(CRP)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P<0.05)。结论:采用雷公藤多苷联合咪唑斯汀治疗皮炎湿疹的疗效理想,减轻临床症状,抑制炎症反应,且安全性好。更多还原

【Abstract】 Objective:To investigate the effect of tripterygium glycosides combined with mizolastine on inflammatory factors in patients with dermatitis and eczema. Methods:92 patients with dermatitis and eczema admitted to our hospital from April 2018 to January 2019 were selected as subjects investigated, and they were randomly divided into a control group and an observation group, 46 cases each. The patients in the control group were treated with mizolastine(10 mg, qd), and the patients in the observation group were treated with tripterygium glycosides [1～1.5 mg/(kg·d)] on the basis of the treatment in the control group. The efficacy, symptom score, inflammatory factors and adverse reactions were compared between the two groups. Results:The total effective rate in the observation group was higher than that in the control group, and the difference was statistically significant(P<0.05). The symptom scores after 1, 2, and 3 weeks of treatment were lower than those before treatment in the two groups, and the scores in the observation group were lower than those in the control group, with statistically significant differences(P<0.05). The levels of interleukin(IL)-2, IL-6 and C-reactive protein(CRP) after treatment were lower than those before treatment in the two groups, and the levels in the observation group were lower than those in the control group, with statistically significant differences(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P<0.05). Conclusion:Tripterygium glycosides combined with mizolastine are ideal in the treatment of dermatitis and eczema, which can relieve clinical symptoms and inhibit inflammatory response, and are safe.更多还原